$314.32
Value $15.5B
CRL and UNH stock compared: price, dividend, valuation and results, from SEC filings.
$314.32
Value $15.5B
$339.85
Value $308B
Charles River Laboratories International (CRL) has a market value of $15.5B and UnitedHealth (UNH) $308B. Over the last year, with dividends, CRL moved +101.8% and UNH +8.2%. Dividend yield: CRL none, UNH 2.67%.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
CRL$15.5B
UNH$308B
UNH is 20 times CRL
Revenue, 12 months
CRL$4.0B
UNH$450B
UNH is 113 times CRL
Net income, 12 months
CRL$40M
UNH$15.9B
UNH is 395 times CRL
Operating margin
CRL4.0%
UNH5.3%
1.3 points apart
ROIC
CRL2.3%
UNH11.3%
9.0 points apart
P/E
CRL–
UNH19.4
Dividend yield
CRL0.0%
UNH2.7%
2.7 points apart
5-year return
CRL-15.4%
UNH-19.5%
4.1 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
CRL-15.4%
UNH-19.5%
| Period | CRLWith dividends | UNHWith dividends |
|---|---|---|
| 1 year since November 18, 2025 | +101.8%Price +101.8% | +8.2%Price +5.4% |
| 3 years since November 17, 2023 | +73.5%+20.2% a yearPrice +73.5% | -34.4%-13.1% a yearPrice -38.4% |
| 5 years since November 18, 2021 | -15.4%-3.3% a yearPrice -15.4% | -19.5%-4.2% a yearPrice -26.5% |
| 10 years since November 21, 2016 | +352.7%+16.3% a yearPrice +352.7% | +159.4%+10.0% a yearPrice +119.7% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
CRLCharles River Laboratories InternationalUNHUnitedHealth
| Price | $314.32 | $339.85 |
|---|---|---|
| Market value | $15.5B | $308B |
| Enterprise value (EV) | $17.7B | $354B |
| P/E | – | 19.4 |
| P/E, 5-year median | 25.6 | 25.0 |
| P/B | 4.8 | 3.0 |
| EV/EBIT | 111.5 | 14.8 |
| Free cash flow yield | 2.6% | 7.4% |
| Revenue, 12 months | $4.0B | $450B |
|---|---|---|
| Net income, 12 months | $40M | $15.9B |
| Free cash flow, 12 months | $400M | $22.8B |
| Earnings per share, 12 months | $0.97 | $17.52 |
| Revenue growth, year on year | -0.9% | 11.8% |
| Revenue growth a year, past | +6.6%over 5 years | +11.7%over 5 years |
| EPS growth a year, past | – | -3.8%over 5 years |
| Gross margin | – | 88.3% |
|---|---|---|
| Operating margin | 4.0% | 5.3% |
| Net margin | 1.0% | 3.5% |
| ROIC | 2.3% | 11.3% |
| ROE | 1.3% | 15.5% |
| Cash | $200M | $28.5B |
|---|---|---|
| Total debt | $2.9B | $74.3B |
| Net debt / EBITDA | 4.0 | 1.6 |
| Interest cover | 1.5× | 6.2× |
| Dividend yield | – | 2.7% |
|---|---|---|
| Dividend per share, 12 months | – | $9.06 |
| Dividend growth a year, past | – | +12.6%over 5 years |
| Buyback yield | 2.3% | 1.8% |
| Shareholder yield | 2.3% | 4.5% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, UnitedHealth ($308B) is about 19.9 times Charles River Laboratories International ($15.5B), at today's prices.
Since November 21, 2016, CRL's price moved +352.7% and UNH's +119.7%. With dividends: CRL +352.7% (+16.3% a year), UNH +159.4% (+10.0% a year). Past returns do not predict future ones.
The dividend yield at today's price is none for Charles River Laboratories International and 2.67% for UnitedHealth. Over the last twelve months they paid – and $9.06 per share.
Over the last twelve months, the net margin was 1.0% for Charles River Laboratories International and 3.5% for UnitedHealth, and the operating margin 4.0% and 5.3%. Revenue was $4.0B and $450B.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.